An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
eMEET (Medicine Evaluation Educational Training) is designed to help patient advocates “navigate the complex world of medicines development, evaluation and assessment.”
It uses video presentations, animations and exercises to show how patients’ experiences are integrated into scientifically based HTA decisions, with training program modules focused on ‘the journey of a medicine’, ‘an introduction to HTA’, ‘HTA in practice’ and ‘patient advocacy group participation in HTA’.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.